63 results
8-K
EX-10.1
ZVRA
Zevra Therapeutics Inc
10 Oct 23
Departure of Directors or Certain Officers
5:12pm
Health Care and Education Reconciliation Act), then in lieu of paying COBRA premiums pursuant to this Section, Company shall pay Executive on the last
424B3
ZVRA
Zevra Therapeutics Inc
10 Oct 23
Prospectus supplement
5:07pm
to health care providers to support the implementation of an element of the REMS.
In addition, drug manufacturers and other entities involved
S-4/A
ZVRA
Zevra Therapeutics Inc
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
a serious risk of the drug, and a communication plan to health care providers to support the implementation of an element of the REMS.
In addition, drug
S-4
3whqs
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
425
9v3 475r1rw8
31 Aug 23
Business combination disclosure
8:03am
8-K
EX-2.1
cavhpfl
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
424B3
k4u43tm3blgm
10 Nov 21
Prospectus supplement
5:19pm
424B3
ejqor hf38
10 Nov 21
Prospectus supplement
5:15pm
8-K
EX-10.1
nr35bub
10 Nov 21
KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates
4:12pm
424B3
y0mgg3r9i lrk9vdn
16 Aug 21
Prospectus supplement
12:00am
424B3
3kvrea223m43o9
12 Jul 21
Prospectus supplement
4:18pm
8-K
EX-10.1
0vf2qfmy4k
2 Jul 21
Entry into a Material Definitive Agreement
4:01pm
D
ks7zh6xpifafpi
22 Jun 21
$39.1M in options / securities to be acquired, sold $39.1M, 12 investors
4:35pm
424B3
nidpjtna05dl3v5wx
13 May 21
Prospectus supplement
9:11pm